Lyra Therapeutics Inc (LYRA)
$0.24
Live
Performance
- $0.24$0.25$0.24
0.63%
Downside
Day's Volatility :4.1%
Upside
3.5%
- $0.21$6.79$0.24
12.29%
Downside
52 Weeks Volatility :96.9%
Upside
96.47%
Returns
| Period | Lyra Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -15.71% | 0.0% |
6 Months | -95.32% | 0.0% |
1 Year | -92.73% | 0.0% |
3 Years | -96.93% | -23.0% |
Highlights
Market Capitalization | 15.2M |
Book Value | $0.47 |
Earnings Per Share (EPS) | -1.56 |
Wall Street Target Price | 1.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -2977.43% |
Return On Assets TTM | -42.36% |
Return On Equity TTM | -156.52% |
Revenue TTM | 1.8M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 30.599999999999998% |
Gross Profit TTM | -34.2M |
EBITDA | -74.3M |
Diluted Eps TTM | -1.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.33 |
EPS Estimate Next Year | -0.74 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.31 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 420.83%
Technicals Summary
Sell
Neutral
Buy
Lyra Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lyra Therapeutics Inc | -10.74% | -95.32% | -92.73% | -96.93% | -98.69% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lyra Therapeutics Inc | NA | NA | NA | -1.33 | -1.57 | -0.42 | NA | 0.47 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lyra Therapeutics Inc | Buy | $15.2M | -98.69% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Lyra Therapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 146.0K → 598.0K (in $), with an average increase of 41.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -15.15M → -48.13M (in $), with an average decrease of 81.3% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 176.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 141.7%
Institutional Holdings
Perceptive Advisors LLC
19.49%Citadel Advisors Llc
7.29%BlackRock Inc
4.32%Samsara BioCapital, LLC
4.25%Vanguard Group Inc
2.64%Ikarian Capital, LLC
1.61%
Company Information
lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.
Organization | Lyra Therapeutics Inc |
Employees | 88 |
CEO | Dr. Harlan W. Waksal M.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.24
-1.64%
Invesco Bulletshares 2025 Hi
$0.24
-1.64%
Schwab International Dividend Equity Etf
$0.24
-1.64%
Blockchain Coinvestors Acquisition Corp.
$0.24
-1.64%
Allgiant Travel Company
$0.24
-1.64%
Rogers Corp
$0.24
-1.64%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.24
-1.64%
Iheartmedia
$0.24
-1.64%
Lightpath Technologies Inc
$0.24
-1.64%